Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody.

Mourad YA, Taher A, Chehal A, Shamseddine A.

Ann Hematol. 2004 May;83(5):319-21. Epub 2003 Nov 27.

PMID:
15060751
2.

Leukemic pleural effusion in B-cell prolymphocytic leukemia.

Andrieu V, Encaoua R, Carbon C, Couvelard A, Grange MJ.

Hematol Cell Ther. 1998 Dec;40(6):275-8.

PMID:
9924927
3.

Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia.

Vartholomatos G, Tsiara S, Christou L, Panteli A, Kaiafas P, Bourantas KL.

Acta Haematol. 1999;102(2):94-8.

PMID:
10529513
4.

Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.

Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S, La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, FoĆ  R.

Haematologica. 2001 Oct;86(10):1046-50.

5.

[Successful treatment by ranimustine (MCNU) of a patient with B-cell prolymphocytic leukemia (B-PLL)].

Wake A, Yamasaki Y, Ogawa R, Mori N, Nagata K, Nakata K, Misago M, Izumi Y, Fujita K, Oda S, et al.

Rinsho Ketsueki. 1993 Nov;34(11):1464-9. Japanese.

PMID:
8254909
6.

Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia.

Crisostomo RH, Fernandez JA, Caceres W.

Leuk Res. 2007 May;31(5):699-701. Epub 2006 Sep 25.

PMID:
16997373
7.

Prolymphocytic leukemia or prolymphocytic transformation of mantle cell lymphoma.

Veillon DM, Nordberg ML, Glass J, Sattar T, Cotelingam JD.

Am J Clin Pathol. 2001 Nov;116(5):781-2. No abstract available.

PMID:
11710698
9.

Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.

Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.

Br J Dermatol. 2005 Jul;153(1):167-73. Review.

PMID:
16029344
10.

T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?

Raynaud P, Caulet-Maugendre S, Foussard C, Salles G, Moreau A, Rossi JF, Patey M, Rousselet MC, Bene MC, Damotte D, Cornillet Lefebvre P, Martin A, Costes V; GOELAMS group.

Hum Pathol. 2008 Feb;39(2):194-200. Epub 2007 Oct 18.

PMID:
17949786
11.

CD3-negative, CD20-positive T-cell prolymphocytic leukemia: case report and review of the literature.

Tamayose K, Sato N, Ando J, Sugimoto K, Oshimi K.

Am J Hematol. 2002 Dec;71(4):331-5. Review.

12.

Skin and gingival lesions in a young woman with B-prolymphocytic leukemia (B-PLL).

Panteli K, Bai M, Basioukas K, Vartholomatos G, Zioga K, Bourantas KL.

J Exp Clin Cancer Res. 2001 Sep;20(3):447-9.

PMID:
11718228
13.

Successful treatment of hairy cell leukemia variant with rituximab.

Narat S, Gandla J, Dogan A, Mehta A.

Leuk Lymphoma. 2005 Aug;46(8):1229-32.

PMID:
16085567
14.

[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].

Al-Ali HK, Wittekind C, Niederwieser D.

Dtsch Med Wochenschr. 2007 Aug;132(33):1688-91. German.

PMID:
17713864
15.

Translocation (8;14)(q24;q32) as the sole cytogenetic abnormality in B-cell prolymphocytic leukemia.

Kuriakose P, Perveen N, Maeda K, Wiktor A, Van Dyke DL.

Cancer Genet Cytogenet. 2004 Apr 15;150(2):156-8.

PMID:
15066324
16.
17.

B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia.

Ruchlemer R, Parry-Jones N, Brito-Babapulle V, Attolico I, Wotherspoon AC, Matutes E, Catovsky D.

Br J Haematol. 2004 May;125(3):330-6. Review.

PMID:
15086413
18.

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.

Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.

Arthritis Rheum. 2007 Dec;56(12):3909-18.

19.

Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy.

Ohno T, Sakamoto T, Mizumoto C, Miyoshi T, Ueda M, Takeoka T, Yamashita K, Hishita T, Hada S.

Int J Hematol. 2006 Jul;84(1):74-8.

PMID:
16867907
20.

[Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].

Iguchi T, Miyazawa K, Okabe S, Kawakubo K, Shimamoto T, Kuriyama Y, Ito Y, Kimura Y, Ohyashiki K, Serizawa H, Iwaya K, Mukai K.

Rinsho Ketsueki. 2004 Oct;45(10):1129-34. Japanese.

PMID:
15553050

Supplemental Content

Support Center